<DOC>
	<DOC>NCT02049164</DOC>
	<brief_summary>The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.</brief_summary>
	<brief_title>Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)</brief_title>
	<detailed_description />
	<criteria>1. Generally healthy female &gt; 40 years of age with a body mass index (BMI) â‰¤ 40; 2. Has undergone menopause defined as any of the following: At least 12 months of spontaneous amenorrhea; or At least 6 months of spontaneous amenorrhea with serum folliclestimulating hormone (FSH) levels &gt; 40 mIU/mL; or At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy); 3. Experience a minimum of 7 moderate to severe hot flushes per day or 50 moderate to severe hot flushes per week 1. Resting systolic blood pressure (SBP) &lt;110 mmHg, resting diastolic blood pressure (DBP) &lt;50 mm Hg, or a resting heart rate (HR) &lt;60 beats per minute while awake; 2. Subjects with preexisting orthostatic hypotension at Screening; 3. Use of oral estrogen, progestin, androgen, or selective estrogen receptor modifier (SERM) containing drug products within 8 weeks prior to Screening; use of transdermal hormone products within 8 weeks prior to Screening; use of vaginal hormone products (rings, creams, gels) within 4 weeks prior to Screening; use of intrauterine progestins within 8 weeks prior to Screening; use of progestin implants or estrogen injectables within 3 months prior to Screening; use of estrogen pellet or progestin injectables within 6 months prior to Screening; 4. History of daily usage (at least 28 days/month) of either of the following during the month prior to initiation of Screening: Antihypertensives or Prophylactic antimigraine medications</criteria>
	<gender>Female</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>AR08, Vasomotor Symptoms</keyword>
</DOC>